Breaking |

Breaking |

Covid-19 vaccine Zydus Cadila get DCGI nod for human clinical trials
Published : Jul 3, 2020, 12:53 pm IST
Updated : Jul 3, 2020, 12:53 pm IST
SHARE ARTICLE
Covid-19 vaccine
Covid-19 vaccine

A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod

New Delhi: A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials.

CoronavirusCoronavirus

Advertisement

The approval process was fast-tracked following recommendation by the subject expert committee on Covid-19.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI in which the vaccine candidate was found to be successful with respect to safety, the source said.

CoronavirusCoronavirusThe phase I and II trials will take around three months to be completed, as per the sources.

Advertisement

The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

SHARE ARTICLE

ROZANA SPOKESMAN

Advertisement
Advertisement

First pictures of Sandeep Sunny after the Patiala Jail attack, police reached hospital For Medical

18 Sep 2025 6:45 PM

Former inspector Suba Singh | PunjabTarn Taran fake encounter case in 1993 News

18 Sep 2025 6:43 PM

After Hoshiarpur another child stolen from Ludhiana Railway station | CCTV Footage | Toddler

18 Sep 2025 6:40 PM

Nihang Singh Clash With Old Man: Nihang Singh used a stick against a person selling cannabis

16 Sep 2025 3:43 PM

Mankirt Aulakh donated tractors controversy: What is the controversy of tractors donated by Aulakh?

16 Sep 2025 3:38 PM

Mohinder KP\'s Son Richi KP Antim Sanskar: Father gives shoulder to son\'s body

16 Sep 2025 3:34 PM
Advertisement